Apollomics, Inc. (APLM )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol APLM
- Company Apollomics, Inc.
- Price $23
- Changes Percentage -18.48
- Change -5.21
- Day Low $22.64
- Day High $26.96
- Year High $42.12
- Year Low $3.66
- Market Cap $25,376,797
- Price Avg 50 EMA (D) $14.53
- Price Avg 200 EMA (D) $8.79
- Exchange NASDAQ
- Volume 13,845
- Average Volume 49,789
- Open $26.96
- Previous Close $28.21
- EPS -52.8
- PE -0.44
- Earnings Announcement 2026-03-26 12:00:00
- Shares Outstanding $1,103,339
Company brief: APOLLOMICS, INC. (APLM )
- Healthcare
- Biotechnology
- Dr. Guo-Liang Yu Ph.D.
- https://www.apollomicsinc.com
- US
- N/A
- 11-26-2021
- KYG0411D1079
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.